Ross, Joseph S. http://orcid.org/0000-0002-9218-3320
Waldstreicher, Joanne
Bamford, Stephen
Berlin, Jesse A.
Childers, Karla
Desai, Nihar R.
Gamble, Ginger
Gross, Cary P.
Kuntz, Richard
Lehman, Richard
Lins, Peter
Morris, Sandra A.
Ritchie, Jessica D.
Krumholz, Harlan M. http://orcid.org/0000-0003-2046-127X
Article History
Received: 28 March 2018
Accepted: 24 October 2018
First Online: 27 November 2018
Competing interests
: In the past 36 months, Drs. Ross, Krumholz, and Ms. Gamble have received research support through Yale University from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585). Drs. Ross, Krumholz, and Desai have received research support from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I). Dr. Ross and Ms. Ritchie have received research support through Yale University from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938). Dr. Ross, Ms. Ritchie, and Ms. Gamble have received research support through Yale University from the Blue Cross Blue Shield Association to better understand medical technology evaluation. Dr. Ross has received research support through Yale University from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. Drs. Waldstreicher and Berlin, Mr. Bamford, Ms. Childers, Mr. Lins, and Dr. Morris are employees of Johnson & Johnson. Dr. Kuntz is an employee of Medtronic, Inc. All other authors declare no competing interests.